NCT06374797Phase 2Terminated

A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04-06Actual

Enrollment · participants122Actual

Source updated2026-08-31Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-31 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~150 participants (planned)~~

+ After

122 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Jul 2026~~

+ After

6 Apr 2026

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Terminated

Check registry source

Posted 2026-05-06 · 1 field changed

Primary completion date changed

− Before

~~Apr 2026~~

+ After

Jul 2026

Check registry source

Posted 2026-02-02 · 2 fields changed

Primary completion date changed

− Before

~~Mar 2026~~

+ After

Apr 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Acute Kidney Injury

Treatments or interventions studied

AuxoraDrug
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Days alive, ventilator-free and kidney replacement therapy (KRT)-free from SFISD through Day 30; description: The primary efficacy analysis will apply the win ratio method and the Finkelstein-Schoenfeld method to the primary endpoints. The win ratio method allocates all Auxora and placebo pairs to the components that comprise the primary endpoint in a hierarchical fashion. Categories (a) and (c) represent Auxora wins based on all-cause mortality and days ventilator-free and KRT-free. Similarly, categories (b) and (d) represent placebo wins. Category (e) represents ties. (a) Death on placebo, but alive on Auxora at day 30 (b) Death on Auxora, but alive on placebo at day 30 (e) Death on placebo and death on Auxora at day 30 If alive on placebo and alive on Auxora at day 30: (c) Greater number of days alive, ventilator-free and KRT-free on Auxora (d) Greater number of days alive, ventilator-free and KRT-free on Placebo (e) Equal number of days alive, ventilator-free and KRT-free We will calculate the overall win ratio by adding (a) + (c) and dividing it by the sum of (b) + (d).; timeFrame: SFISD through Day 30

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history